|
Malignant neoplasm of breast
|
0.100 |
Biomarker
|
disease |
BEFREE |
This study demonstrates for the first time that mitochondrial thiol modification inhibits metabolism via inhibition of both aconitase and GAC in a breast cancer cell model.
|
26774751 |
2016 |
|
Malignant neoplasm of breast
|
0.100 |
Biomarker
|
disease |
BEFREE |
The results also demonstrated that knock‑down of GLS1 using small interfering RNA, resensitized the Taxol‑resistant breast cancer cells to Taxol.
|
25625774 |
2015 |
|
Malignant neoplasm of breast
|
0.100 |
Biomarker
|
disease |
BEFREE |
SIRT5 stabilizes mitochondrial glutaminase and supports breast cancer tumorigenesis.
|
31843902 |
2019 |
|
Febrile Convulsions
|
0.100 |
Biomarker
|
disease |
HPO |
|
|
|
|
Progressive cerebellar ataxia
|
0.100 |
Biomarker
|
disease |
HPO |
|
|
|
|
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
This study has identified GLS a potential therapeutic target in breast cancer, specifically in the basal subtype that exhibits a deregulated glutaminolysis pathway.
|
28950000 |
2017 |
|
Breast Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Triple-negative (TN) breast cancer (testing negative for estrogen, progesterone, and Her2 receptors) has elevated GLS protein levels and reportedly depends on exogenous glutamine and GLS activity for survival.
|
31541193 |
2020 |
|
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
SIRT5 stabilizes mitochondrial glutaminase and supports breast cancer tumorigenesis.
|
31843902 |
2019 |
|
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The results also demonstrated that knock‑down of GLS1 using small interfering RNA, resensitized the Taxol‑resistant breast cancer cells to Taxol.
|
25625774 |
2015 |
|
Breast Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Molecular cloning, sequencing and expression studies of the human breast cancer cell glutaminase.
|
10620514 |
2000 |
|
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Tumors of this subtype had a stem cell-like transcriptional signature and tended to overexpress glutaminase, suggestive of a functional relationship between glutamine and 2HG metabolism in breast cancer.
|
24316975 |
2014 |
|
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Treatment of non-invasive epithelial (T-47D and MDA-MB-361) and invasive mesenchymal (MDA-MB-231 and Hs-578T) breast cancer cell lines with the glutaminase inhibitor, Compound 968, resulted in cytotoxicity in all cell lines, with the greatest effect being observed in MDA-MB-231 breast cancer cells.
|
23117580 |
2012 |
|
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
These results demonstrate in a mouse model of breast cancer the utility of GluCEST MRI to detect the early response to glutaminase inhibition.<b>Significance:</b> A sensitive method enables noninvasive detection of tumor response to inhibitors of glutamine metabolism.<i></i>.
|
30072394 |
2018 |
|
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
<sup>13</sup>C HR MAS MRS analysis of tumor tissue from CB-839-treated and untreated models receiving <sup>13</sup>C-labeled glutamine ([5-<sup>13</sup>C] Gln) shows that the glutaminase inhibitor CB-839 is causing an accumulation of glutamine (arrow up) in two PDX models representing luminal-like breast cancer (MAS98.06) and basal-like breast cancer (MAS98.12).
|
31088535 |
2019 |
|
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The first complete sequence of human L-glutaminase was deduced from breast cancer glutaminase cDNA cloned in our laboratory.
|
12758143 |
2003 |
|
Breast Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Inhibition of MYC, SLC1A5 and GLS decreased AI resistant breast cancer cell proliferation.
|
25683269 |
2015 |
|
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
This study demonstrates for the first time that mitochondrial thiol modification inhibits metabolism via inhibition of both aconitase and GAC in a breast cancer cell model.
|
26774751 |
2016 |
|
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Transcriptional analyses revealed that the expression levels of genes linked to lipid metabolism were altered between sensitive and resistant cells and between breast cancer tissues (available from The Cancer Genome Atlas project) with low <i>versus</i> high glutaminase (<i>GLS</i>) gene expression.
|
31040181 |
2019 |
|
Breast Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Finally, knockdown or inhibition of GLS1 significantly decreased the proliferation of breast cancer cells with high GLS1 levels.
|
24122876 |
2014 |
|
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Blocking the conversion of glutamine to glutamate using an allosteric inhibitor, Compound 968, against GLS1, increased H4K16ac in T-47D and MDA-MB-231 cells, linking glutamine metabolism to a particular histone modification in breast cancer.
|
22101407 |
2012 |
|
Hyperkeratosis
|
0.100 |
Biomarker
|
disease |
HPO |
|
|
|
|
Respiratory Failure
|
0.100 |
Biomarker
|
disease |
HPO |
|
|
|
|
Gross motor development delay
|
0.100 |
Biomarker
|
disease |
HPO |
|
|
|
|
Neonatal Hypotonia
|
0.100 |
Biomarker
|
disease |
HPO |
|
|
|
|
Liver carcinoma
|
0.090 |
AlteredExpression
|
disease |
BEFREE |
We reported Gankyrin increases glucose consumption, lactate production, glutamine consumption and glutamate production in HCC through upregulating the expression of the transporters and enzymes involved in glycolysis and glutaminolysis, including HK2, GLUT1, LDHA, PKM2, ASCT2 and GLS1.
|
30503555 |
2019 |